Original Research Article

Synthetic curcuminoid analogues abrogate oxidation-induced cell death and promote myogenic differentiation of C2C12 mouse myoblasts

Chittipong Tipbunjong1*, Piyawat Sookbangnop2, Vachiraporn Ajavakom3, Apichart Suksamrarn3, Yindee Kitiyanant4, Chumpol Pholpramool5

1Department of Anatomy, 2Department of Biology, Faculty of Science, Prince of Songkla University, Songkhla 90112, 3Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Ramkhamhaeng University, Bangkok 10240, 4Department of Anatomy, 5Department of Physiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

*For correspondence: Email: chittipong.t@psu.ac.th; Tel: +66 92 6345297

Sent for review: 19 April 2018 Revised accepted: 25 July 2018

Abstract

Purpose: To investigate the ability of two synthetic curcuminoid analogues, 6-(4-hydroxy-3-methoxyphenethyl)-5-(3-(4-hydroxy-3-methoxyphenyl)propanoyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (compound A) and 6-(4-hydroxy-3-methoxyphenethyl)-4-(4-hydroxy-3-methoxyphenyl)-5-(3-(4-hydroxy-3-methoxyphenyl)propanoyl)-3,4-dihydropyrimidin-2(1H)-one (compound B), to protect against oxidation-induced cell death and the potential to enhance proliferation and differentiation of C2C12 myoblast cells.

Methods: Antioxidant activity of curcumin analogues was evaluated by DPPH assay. The cytotoxic activity of the compounds (0 - 25 mM) on C2C12 myoblasts was determined by MTT assay while the effect on cell proliferation was assessed by BrdU uptake. Myoblast cell differentiation was measured by the formation of myotubes and myosin heavy chain (MHC) protein expression using immunofluorescence staining and Western blotting, respectively.

Results: Both curcumin analogues exhibited strong anti-oxidant activity of up to 3-fold greater than that of ascorbic acid, and were non-toxic to C2C12 myoblasts at concentrations up to 25 mM. Furthermore, these curcumin analogues mitigated myoblast cell death induced by oxidative stress. Notably, both analogues (10 nM) had no effect on cell proliferation. However, only compound A significantly enhanced myoblast differentiation comparable to the effects of dihydrotestosterone (1 µM) and estradiol (10 nM).

Conclusion: The results suggest that compound A may serve as a lead compound for the development of suitable therapeutic agents for muscle injuries and diseases.

Keywords: Curcuminoid analogues, Antioxidant, Cell proliferation, Cell differentiation, Myoblasts

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.


INTRODUCTION

Skeletal muscle mass and strength are progressively lost with aging leading to the decline in functional ability known as sarcopenia [1]. One of the most important factors that could play a key role in triggering sarcopenia is the oxidative stress. In aging conditions, the
production of reactive oxygen species (ROS) is enhanced while the anti-oxidative capacity is diminished [2] resulting in cellular oxidative stress critical for cell death. Under this condition, the proliferation and differentiation capacities of satellite cells, which are required for muscle repair and/or regeneration, decrease [1] leading to a gradual decline in muscle mass and function.

The expression of acetylcholinesterase (AChE) involves the regulation of cell proliferation, differentiation, and survival. For example, myogenic differentiation of C2C12 cells is associated with an increased expression of AChE [3]. In addition, an upregulation of AChE has been shown after induction of apoptosis by different types of stimuli in various cells [4]. On the other hand, an overexpression of this enzyme has been shown to affect cell-cycle in differentiating cells [5], inhibit cell proliferation and promote apoptosis [6,7]. Although AChE is not a universal activator of apoptosis, it enhances sensitivity to cell death [6]. In addition, AChE involved with cellular apoptosis by implicating in apoptosome formation in various cell types [8]. Recently, we have synthesized a series of curcuminoid analogues in moderate to good yields and showed that they have an anticholinesterase activity suggesting their potential for therapeutic applications in anti-neurodegenerative diseases such as Alzheimer’s disease [9]. However, other biological properties of these compounds have not yet been investigated.

The purposes of this study were to evaluate the antioxidant property of two synthetic curcuminoid analogues and to investigate their abilities to protect myoblasts against oxidative-induced cell death. Furthermore, the potential of these compounds to enhance myoblast proliferation and differentiation were determined.

EXPERIMENTAL

Reagents

Unless otherwise indicated, cell culture reagents were purchased from Gibco (CA, USA) and basic chemical reagents and primary antibody were obtained from Sigma-Aldrich (MO, USA). Mouse monoclonal anti-MHC and Western HRP substrate were from Millipore (MA, USA).

Synthesis of curcuminoid analogues

Curcuminoid analogues, 6-(4-hydroxy-3-methoxyphenethyl)-5-(3-(4-hydroxy-3-methoxyphenyl)propanoyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (compound A) and 6-(4-hydroxy-3-methoxyphenethyl)-4-(4-hydroxy-3-methoxyphenyl)-5-(3-(4-hydroxy-3-methoxyphenyl)propanoyl)-3,4-dihydropyrimidin-2(1H)-one (compound B), were synthesized and characterized as previously described [9]. Their chemical structures are illustrated in Figure 1.

Cell culture

C2C12 mouse myoblast cell line was purchased from American Type Culture Collection (VA, USA). Cells were maintained in growth medium (GM; DMEM supplemented with 10 % fetal bovine serum) and 1% antibiotic at 37 °C in a humidified 5 % CO₂ incubator.

The cell cycle stage of the subconfluence cells were synchronized by being cultured in DMEM for 24 h. The cells were then transferred to GM containing various concentrations of compound A or B or dihydrotestosterone or 17β-estradiol for another 24 h. The treated cells were subjected to MTT assay for cytotoxicity and cell proliferation determination.

The confluent cells were cultured in differentiation medium (DMEM supplemented with 2 % horse serum) containing curcuminoid analogues or 17β-estradiol (E2) or dihydrotestosterone (DHT) for 5 days to stimulate myoblast differentiation. After treatment, differentiated cells were washed and then fixed with cold methanol for immunofluorescence staining or harvested protein for Western blot analysis.

MTT assay

Cell viability was determined by a reaction with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) according to the protocol described previously [10]. The treated cells were incubated with GM containing MTT at 0.5 mg/mL final concentration for 4 h. Thereafter, the solution was discarded and replaced with 100 μL solubilizing solution.
The absorbance was measured at 570-630 nm using a microplate reader (BioTek, VT, USA).

DPPH assay

Free radical scavenging capacity was measured by a reaction with 2,2'-diphenyl-1-picrylhydrazyl (DPPH) radical. The aliquots (100 µL) of 400 µM DPPH were mixed with various concentrations of 100 µL curcuminoid compounds or ascorbic acid in a 96-well plate. Following 30 min incubation, the absorbance at 517 nm was measured. Radical scavenging capacity (RSC) was calculated using Equation 1 [11]:

\[ RSC (%) = 100 - ((A - B)/C) \times 100 \]  

where A is the absorbance of the probe; B is the absorbance of the extract alone, and C is the absorbance of the DPPH radical alone. The radical scavenging capacity was shown as 50 % inhibition concentration (IC_{50}).

BrdU incorporation assay

The number of proliferating cells in S-phase was detected by BrdU incorporation assay. At 3 h before harvested, an aliquot of BrdU solution was directly added into the medium of the treated cells at 10 mM final concentration. The harvesting cells were then fixed with cold methanol for 10 min before processed to immunofluorescence staining.

Induction of cell death

C2C12 myoblasts were pretreated with compound A or B at the indicated concentration for 24 h. Then, the pretreated cells were transferred to a medium containing 0.8 mM H_{2}O_{2} for 24 h to induce cell death by 80 % [12]. Cell viability was measured by MTT assay as described above.

Immunofluorescence staining

The fixed cells were washed and rehydrated in PBS. Cells were permeabilized and blocked the nonspecific binding with 5 % normal goat serum diluted in PBS for 1 h. The primary antibody diluted in PBS was applied to cells and then incubated overnight at 4 °C. After several times of washings, cells were incubated with a secondary antibody conjugated with fluorescence dye and Hoechst 33342 for 45 min. The staining signals were visualized under a fluorescence microscope (Olympus IX73; MI, Italy).

Western blotting

The treated cells were washed and subjected to protein extraction using a RIPA buffer with a protease inhibitor. Protein was separated by centrifugation and then concentration was determined using BCA kit. An equal amount of protein (20 µg) was resolved on 10% SDS-PAGE and transferred to PVDF membrane. To block the nonspecific binding, blots were incubated with 0.5% skim milk in PBS and were then probed with primary antibody for 1 h at RT. After several times washed, blots were incubated with appropriate secondary antibody conjugated with HRP. The resulting bands were visualized with Western HRP substrate. The image J software was used to quantify the band intensity.

Statistical analysis

All data are expressed as a mean ± standard error of the mean (SEM) of at least three independent experiments. Statistical significance between groups was analyzed by one-way analysis of variance (ANOVA) with Tukey’s post hoc test. All statistical analysis were conducted by IBM SPSS version 19 with p-value set at *p < 0.05,**p < 0.01, or ***p < 0.001.

RESULTS

Cytotoxicity and antioxidant activity

Both curcuminoid analogues at concentrations up to 25 µM showed no effect on C2C12 myoblast cell viability determined by MTT assay. Instead, significant enhancements of cell viability at concentrations lower than 10 µM were observed (Table 1). Based on MTT assay which detects the living, but not dead cells, these data indicate that the number of living myoblast cells in curcuminoid treatment groups was increased. Such an increment may be due to enhanced myoblast cell proliferation and/or reduced cell death. BrdU incorporation assay was, therefore, used to detect the proliferating cells during the S-phase.

Table 2: Antioxidant activity of curcuminoid analogues; mean ± SEM (n = 4)

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC_{50} (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>18.6 ± 0.1</td>
</tr>
<tr>
<td>B</td>
<td>17.4 ± 0.1</td>
</tr>
<tr>
<td>Ascorbic acid</td>
<td>47.8 ± 0.1</td>
</tr>
</tbody>
</table>
Table 1: Cytotoxicity of curcuminoid analogues; mean ± SEM (n = 4)

<table>
<thead>
<tr>
<th>Compound</th>
<th>Control</th>
<th>0.01</th>
<th>0.1</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>100 ± 3.3</td>
<td>160.8 ± 7.8***</td>
<td>156.1 ± 5.6***</td>
<td>155.3 ± 10.4**</td>
<td>136.5 ± 9.2**</td>
<td>109.0 ± 3.0</td>
<td>106.7 ± 9.1</td>
</tr>
<tr>
<td>B</td>
<td>100 ± 3.3</td>
<td>145.1 ± 7.1***</td>
<td>136.4 ± 7.8**</td>
<td>129.4 ± 6.4**</td>
<td>125.7 ± 6.1**</td>
<td>109.0 ± 3.4</td>
<td>108.4 ± 2.5</td>
</tr>
</tbody>
</table>

Since most aromatic ring compounds that exhibit antioxidant activity [13,14] favor cell viability, the antioxidant property of curcuminoid analogues was investigated using the DPPH assay. Indeed, both compounds exhibited a potent antioxidant activity (IC$_{50}$ of 18.6 ± 0.1 and 17.4 ± 0.1 µM, respectively) when compared to that of ascorbic acid (IC$_{50}$ of 47.8 ± 0.1 µM) (Table 2).

C2C12 myoblast cell proliferation

As shown in Table 1, both compounds significantly increased the cell viability at low concentration. This may result from an increase in cell proliferation and/or a decrease in cell death. To delineate these possibilities, BrdU incorporation assay was performed. The results showed that both compounds and E2 did not alter the number of cells in S-phase whereas BrdU uptake was significantly increased in the DHT treatment group (Figure 2). This result suggests that the compounds suppressed cell death but not enhanced cell proliferation.

Protective activity on cell death

Figure 2: Proliferation of C2C12 myoblast assessed by BrdU uptake. (A) Representative photographs of BrdU-positive nuclei (red), BrdU-negative nuclei (blue), and merge (pink) after treatments with curcuminoid analogues (10 nM), E2 (10 nM), or DHT (1 µM) for 24 h. (B) Quantitative analysis of BrdU-positive cells expressed as percent of control. Scale bar = 100 µm

Figure 3: Protective effect of curcuminoid analogues on H$_2$O$_2$ toxicity in C2C12 cells. The ability of compound A (A) and compound B (B) to prevent cell death induced by H$_2$O$_2$.  

\[ Trop J Pharm Res, August 2018; 17(8):1486 \]
Oxidative stress is a risk factor for the development of apoptosis and inflammation during muscle regeneration. Anti-oxidation is therefore the key mechanism for preventing those and for improving muscle regeneration efficiency. Our results showed that pretreatment with compound A and compound B, at concentration 5 and 15 µM, respectively, significantly mitigated C2C12 cell death induced by 0.8 mM H₂O₂ up to 60% compared to 75% in E2 pretreated group (Figure 3). This suggests ROS scavenging action.

C2C12 myoblast cell differentiation

The confluence cells were induced to differentiate into myotubes in the presence of the test compounds. Results showed that compound A, but not compound B, significantly enhanced C2C12 myoblast differentiation by increasing the numbers and size of myotubes (Figure 4), and MHC protein expression up to 1.5 folds (Figure 5). The enhancement of myoblast differentiation induced by compound A was comparable to those of DHT and E2.

DISCUSSION

Our results corroborate those of other studies showing that diarylethenoids from Curcuma cumosa Roxb are non-cytotoxic to several non-cancer cell lines at the concentration lower than 100 µM [13,15-16]. Similarly, the effects of other diarylethenoids from other plant species depend on the concentration and/or the cell types being tested [17,18]. Of note, the diarylethenoids, even from different species, are well-known for antioxidant activity [13,14]. Several lines of evidence indicate that the presence of hydroxyl groups on aromatic rings is required for the antioxidant activity. The degree of such activity mainly depends on the numbers and positions of hydroxyls on the nuclear structure. Multiple hydroxyls are favorable for the activity, while mono- and di-hydroxyls exhibit no detectable activity [19].

Figure 4: Enhancement of C2C12 myoblast differentiation by curcuminoid analogues. Representative photographs showing MHC positive myotubes (green, arrowhead) and nuclei (blue) staining after induction of differentiation in the presence of curcuminoid analogues (10 nM), E2 (10 nM), or DHT (1 µM) for 5 days. Scale bar = 100 µm

Figure 5: Enhancement of MHC protein expression by curcuminoid analogues. (A) Representative blots of MHC and tubulin after treatment with each curcuminoid analogue (10 nM) compared to E2 (10 nM) and DHT (1 µM) for 5 days. (B) Quantitative band intensity of MHC normalized with tubulin and expressed as fold changes to control

Even though curcumin, a well-known diarylethenoid, has been reported to stimulate muscle precursor cell proliferation under appropriate conditions [20], only some diarylethenoid compounds from Curcuma comosa exhibit a proliferative effect on C2C12 myoblast cells [12]. These compounds also have been shown to promote proliferation in MC3T3-E1 mouse pre-osteoblast [15] and human osteoblast cells [16]. Such a variable impact effect on cell proliferation maybe due to the type
and concentration of compounds, and cell types being tested.

The free radical scavenging occurs through enzyme and non-enzyme mechanisms, the latter takes place through compounds widely present in natural plants. Curcuminoid analogues used in this study has been reported to inhibit acetylcholinesterase activity [9], which is expressed after apoptosis induced by different stimuli [4]. Other diarylheptanoids from different plant species also exhibit a protective effects on cell death induced by different chemicals. For example, acerogenin A from Acer nikoense showed a protective effect against glutamate-induced neurotoxicity in mouse hippocampal HT22 cells [21]. Two other diarylheptanoids from the bark of black alder (Alnus glutinosa) significantly antagonized the effects of doxorubicin-induced cell death in human normal keratinocytes [22]. The current research indicates that diarylheptanoids play a key role in cellular protection against cell death induced through PI3K/Akt and Nrf2 signaling pathways [21]. The results, therefore, confirm previous studies and further illustrate that this activity of the diarylheptanoids is not limited to human retinal epithelial cells, human normal keratinocytes, rat hepatocytes, and mouse hippocampal cells but also extends to mouse myoblasts.

The effect of curcuminoids on myoblast differentiation has been reported to show a biphasic effect. Thus, curcumin at low concentration (1 μM) promoted primary mouse myoblast differentiation both in vitro and in vivo studies by increasing MHC level up to 3-folds [20]. On the other hand, high concentration (20 μM) of curcumin significantly inhibited myoblast differentiation by suppressing myogenin and MHC expression [23]. The stimulatory effect of curcuminoids on cell differentiation is not limited only to myoblasts. They also stimulated cell differentiation of MC3T3-E1 mouse pre-osteoblasts [15] and NB-39 neuroblastoma [17]. The action of curcuminoids on myoblast differentiation is abolished by ICI 182,780, suggesting that curcuminoids enhance myoblast differentiation by activating ER [12]. In addition, curcuminoids also mediate their activity through the ER to enhance differentiation in osteoblasts [15,16]. Notably, the results showed that only compound A, but not compound B, enhanced myoblast differentiation. This may be due to its ability to adjust its alignments suitable for ER activation. Of note, curcuminoids possess the biphenolic structure similar to E2, as well as the presence of hydroxyl groups, which is required for binding with ER. Whether or not the effect on myoblast differentiation is involved with binding to ER warrants further investigations.

CONCLUSION

The findings of this study show that synthetic curcuminoid compound A and B are not toxic to C2C12 mouse myoblasts. These compounds also exhibit antioxidant activity that is greater than that of ascorbic acid. Moreover, they mitigate cell death induced by H2O2. Although both compounds do not enhance cell proliferation, however, compound A enhances myogenic differentiation of myoblasts comparable to the effects of DHT and E2. Therefore, the ability of compound A to prevent muscle wasting and/or enhance muscle regeneration after injury indicates that it is a potential therapeutic agent for the treatment of muscle injury and/or diseases.

DECLARATIONS

Acknowledgement

This work was supported by: The Thailand Research Funds (DBG 5980003); Center of Excellence for Innovation in Chemistry, Office of the Higher Education Commission; Department of Anatomy and Department of Physiology, Faculty of Science, Mahidol University.

Conflict of Interest

No conflict of interest associated with this work.

Contribution of Authors

The authors declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by them.

REFERENCES


